Genome-based therapeutics : : targeted drug discovery and development : workshop summary / / Adam C. Berger and Steve Olson, Rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
"The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in...
Saved in:
| TeilnehmendeR: | |
|---|---|
| Place / Publishing House: | Washington, District of Columbia : : National Academies Press,, [2012] 2012 |
| Year of Publication: | 2012 |
| Language: | English |
| Online Access: | |
| Physical Description: | 1 online resource (109 pages) :; illustrations |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Introduction
- The current landscape
- Case studies: The development of Crizotinib for treatment of non-small-cell lung cancer; Use of genetics to inform drug development for the treatment of schizophrenia; A genetic approach to the treatment of cystic fibrosis
- Emerging technologies in drug development: Large-scale whole-genome sequencing; The value of clinical next-generation sequencing to drug developers; The uses of genomic information
- Evolving paradigms: Foundations and drug development: an example; Genomics and regulatory science; Pharmacy benefit management and pharmacogenomics; Repurposing of drugs
- Forging collaborative strategies for the development of personalized medicine: The need for collaboration; FDA initiatives; NCATS initiatives; Biospecimens and databases; Reducing health disparities; Patient and physican education; An emphasis on the science.